Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.48 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.48 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.48 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | F7 | P08709 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CTSV | O60911 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14080472 | 1.00 | ADRB2 (0.48) | ADRB2ADRB1ADRB3F2F7 | |
| SCHEMBL14080487 | 1.00 | ADRB2 (0.48) | ADRB2ADRB1ADRB3F2F7 | |
| Cadaverine Tartrate SCHEMBL14080565 | 0.96 | F2 (0.46) | ADRB2ADRB1ADRB3F2F7 | |
| SCHEMBL11748288 | 0.92 | ADRB2 (0.49) | ADRB2ADRB1ADRB3F2F7 | |
| SCHEMBL8077438 | 0.91 | FOLH1 (0.51) | ADRB2ADRB1ADRB3MEN1KMT2A | |
| SCHEMBL11596019 | 0.89 | ADRB2 (0.47) | ADRB2ADRB1ADRB3F2F7 | |
| SCHEMBL965193 | 0.84 | F2 (0.49) | ADRB2ADRB1ADRB3F2F7 | |
| SCHEMBL965192 | 0.84 | F2 (0.49) | ADRB2ADRB1ADRB3F2F7 | |
| SCHEMBL7109940 | 0.82 | F2 (0.47) | ADRB2ADRB1ADRB3F2F7 | |
| Iodide SCHEMBL9574103 | 0.81 | F2 (0.47) | ADRB2ADRB1ADRB3F2F7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43984-E1 | Process for preparing isomers of salbutamol | CIPLA LIMITED (IN) | 2013-02-05 | — | — | US | claimed |
| US-RE43844-E1 | Process for preparing isomers of salbutamol | CIPLA LIMITED (IN) | 2012-12-04 | — | — | US | claimed |
| US-6995286-B2 | Resolution of racemic mixture using tartaric acid | CIPLA LIMITED (IN) | 2006-02-07 | — | — | US | claimed |
| EP-0763010-B1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 2000-08-30 | — | — | EP | claimed |
| EP-0763010-A4 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR INC (US) | 1997-07-16 | — | — | EP | claimed |
| EP-0763010-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1997-03-19 | — | — | EP | claimed |
| US-5545745-A | DISSOLVING MIXTURE OF METHYL-5(2-(1,1-DIMETHYLETHYL)AMINO)-1-HYROXYETHYL)-2-(PHENYL -METHOXY)BENZOATE AND A CHIRAL ACID, SALT FORMATION, COOLING, NEUTRALIZING SALT WITH BASE, REDUCTION, DEBENZYLATION | SEPRACOR, INC. (US) | 1996-08-13 | — | — | US | claimed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | claimed |
| US-20240391866-A1 | PROCESS FOR THE PREPARATION OF THE SALBUTAMOL INTERMEDIATE | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2024-11-28 | — | — | US | disclosed |
| US-RE43984-E1 | Process for preparing isomers of salbutamol | CIPLA LIMITED (IN) | 2013-02-05 | — | — | US | disclosed |
| US-RE43844-E1 | Process for preparing isomers of salbutamol | CIPLA LIMITED (IN) | 2012-12-04 | — | — | US | disclosed |
| EP-1935872-A1 | Process for obtaining the R-enantiomer of salbutamol | Stirling Products Limited (AU) | 2008-06-25 | — | — | EP | disclosed |
| WO-2008070909-A1 | PROCESS FOR OBTAINING THE R-ENANTIOMER OF SALBUTAMOL | STIRLING PRODUCTS LIMITED (AU) | 2008-06-19 | — | — | WO | disclosed |
| WO-2007101872-A1 | PROCESS FOR THE ENANTIOMERIC ENRICHMENT OF SALBUTAMOL AND SALBUTAMOL PRECURSORS | STIRLING PRODUCTS LTD. (AU) | 2007-09-13 | — | — | WO | disclosed |
| EP-0763010-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| EP-0763010-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| US-5545745-A | DISSOLVING MIXTURE OF METHYL-5(2-(1,1-DIMETHYLETHYL)AMINO)-1-HYROXYETHYL)-2-(PHENYL -METHOXY)BENZOATE AND A CHIRAL ACID, SALT FORMATION, COOLING, NEUTRALIZING SALT WITH BASE, REDUCTION, DEBENZYLATION | SEPRACOR, INC. (US) | 1996-08-13 | — | — | US | disclosed |
| US-5545745-A | DISSOLVING MIXTURE OF METHYL-5(2-(1,1-DIMETHYLETHYL)AMINO)-1-HYROXYETHYL)-2-(PHENYL -METHOXY)BENZOATE AND A CHIRAL ACID, SALT FORMATION, COOLING, NEUTRALIZING SALT WITH BASE, REDUCTION, DEBENZYLATION | SEPRACOR, INC. (US) | 1996-08-13 | — | — | US | disclosed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
| WO-1995032178-A1 | ENANTIOSELECTIVE PREPARATION OF OPTICALLY PURE ALBUTEROL | SEPRACOR, INC. (US) | 1995-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391866-A1 | PROCESS FOR THE PREPARATION OF THE SALBUTAMOL INTERMEDIATE | ADRB3, ADH1C, ADRB2 | ADRB2 3/4885ADRB1 4/4885ADRB3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.